Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Extended treatment
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Fractional CO2 Laser
Hospital Authority, Hong Kong
Treatments of Striae Gravidarum
1 trial -
Grafalon 20 mg/ml concentrato per soluzione per infusione
The George Institute
To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.
1 trial -
HEPARIN , NADROPARIN
Disc Medicine
All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.
1 trial -
Household-based water treatment with NADCC tablets
United Therapeutics Europe Ltd
Diarrhoea
1 trial -
Infrared ray heat treatment
The First People's Hospital of Lianyungang
Liver Cirrhosis
1 trial -
Internet-based smoking treatment
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Irinotecan liposome、5-Fluorouracil、Leucovorin
Jian Li
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
1 trial -
KY2025-328-02
The First People's Hospital of Lianyungang
Post-stroke Epilepsy
1 trial -
LP0162-1336
LEO Pharma A/S
Treatment of moderate-to-severe Atopic dermatitis
1 trial -
Lapaquistat acetate and current lipid-lowering treatment
Takeda
Hypercholesterolemia
1 trial -
Lu AF35700
H. Lundbeck A/S
Treatment-resistant Schizophrenia
1 trial -
MK-2870-020
Merck Sharp and Dohme
Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.
1 trial -
MK-2870-023
Merck Sharp and Dohme
Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)
1 trial -
MaaT013
Lacuna Pharma Pty Ltd
Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
1 trial -
Methadone Treatment-As-Usual
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use
1 trial -
N-Acetylcysteine (NAC) Treatment
The First People's Hospital of Lianyungang
Thrombotic Microangiopathy
1 trial -
NGAM-16
Maze Therapeutics
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
1 trial -
NW-3509/023/III/2024
Lacuna Pharma Pty Ltd
treatment-resistant schizophrenia (TRS)
1 trial -
PICO-TRAT
Lacuna Pharma Pty Ltd
Second line treatment for colonoscopy preparation
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Adjunctive Treatment of Major Depressive Disorder
3 trials -
Psilocybin
Compass Therapeutics
Treatment Resistant Depression
7 trials -
Qarziba 4.5 mg/mL concentrate for solution for infusion
COLLEGIUM PHARMACEUTICAL, INC
Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.
1 trial -
RT2019-13
Disc Medicine
Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.